Clinical Trial Update: Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia [Phase 1, Phase 2]

View source ↗

Summary

NHLBI-sponsored clinical trial update describes adding JSP191, a C-kit antibody, to a nonmyeloablative hematopoietic cell transplantation regimen for sickle cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Sickle Cell Disease

Drugs mentioned

• JSP191

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Sickle Cell Anemia, Beta Thalassemia | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING